Microbiology of Bacteria Causing Recurrent Acute Otitis Media (AOM) and AOM Treatment Failure in Young Children in Spain: Shifting Pathogens in the Post-pneumococcal Conjugate Vaccination Era
Overview
Authors
Affiliations
Objective: To prospectively identify the bacterial aetiology and antimicrobial susceptibility of problematic (recurrent and treatment failure) acute otitis media in Spanish children several years after the introduction of 7-valent pneumococcal conjugate vaccine.
Methods: Tympanocentesis or careful sampling of spontaneous otorrhoea was performed on children aged 3 to <36 months with recurrent acute otitis media, acute otitis media treatment failure or unresolved acute otitis media.
Results: 105 acute otitis media episodes (77 sampled by tympanocentesis, 28 otorrhoea samples) were evaluated: 46 recurrent, 35 treatment failures, 24 unresolved acute otitis media. 74 episodes (70.4%) had at least one bacterium identified on culture: Streptococcus pneumoniae was identified in 21 episodes, Haemophilus influenzae (all non-typeable) in 44, Streptococcus pyogenes in 2, Moraxella catarrhalis in 2. No statistically significant difference in bacterial aetiology by episode type was detected. Non-typeable H. influenzae was the most commonly isolated pathogen in all acute otitis media types and in all age sub-groups. Forty percent of S. pneumoniae isolates were multi-drug resistant. Pneumococcal serotype 19A was the most frequently identified serotype (7/21 episodes). Multi-drug resistance was found in 56% of 19A isolates. Of non-typeable H. influenzae isolates, 15% were ampicillin resistant and 13% were amoxicillin/clavulanate resistant. S. pneumoniae and non-typeable H. influenzae DNA were each detected in 57% of samples culture negative for these pathogens, including 12 co-infections.
Conclusion: Combining culture and polymerase chain reaction results, H. influenzae and S. pneumoniae may be implicated in 70% and 43% of clinically problematic bacterial acute otitis media episodes, respectively. The impact of new vaccines to prevent both S. pneumoniae and non-typeable H. influenzae acute otitis media may be substantial in this population and is worth investigating.
Ricci Conesa H, Skroder H, Norton N, Bencina G, Tsoumani E PLoS One. 2024; 19(4):e0297098.
PMID: 38564583 PMC: 10986968. DOI: 10.1371/journal.pone.0297098.
Duff A, Jurcisek J, Kurbatfinski N, Chiang T, Goodman S, Bakaletz L NPJ Biofilms Microbiomes. 2024; 10(1):10.
PMID: 38310144 PMC: 10838340. DOI: 10.1038/s41522-024-00481-0.
Abavisani M, Keikha M, Karbalaei M BMC Infect Dis. 2024; 24(1):90.
PMID: 38225571 PMC: 10789054. DOI: 10.1186/s12879-023-08930-5.
New insights into the treatment of acute otitis media.
El Feghaly R, Nedved A, Katz S, Frost H Expert Rev Anti Infect Ther. 2023; 21(5):523-534.
PMID: 37097281 PMC: 10231305. DOI: 10.1080/14787210.2023.2206565.
Incidence of acute otitis media from 2003 to 2019 in children ≤ 17 years in England.
Mohanty S, Podmore B, Cunado Moral A, Weiss T, Matthews I, Sarpong E BMC Public Health. 2023; 23(1):201.
PMID: 36717794 PMC: 9885604. DOI: 10.1186/s12889-023-14982-8.